4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
US6380209B1 · kind B1 · utility
3Cited by
5References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 30, 2000 |
| Grant date | Apr 30, 2002 |
| Priority date | — |
| Expiry date | May 30, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are compounds of the formula or the pharmaceutically acceptable non-toxic salts thereof wherein:R is hydrogen, alkyl, or(un)substituted alkoxy or amino; andW is (un)substituted alkyl, aryl, or heteroaryl,which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. The compounds of the invention are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.